¿Es posible incrementar la supervivencia global en cáncer diferenciado de tiroides tras la refractariedad al radioiodo?

11 / 30

Sorafenib Treatment Was Associated With
Significantly Longer PFS Vs Placebo
n
Median PFS, mo
Sorafenib 207 10.8
Placebo 210 5.8
PFS Probability, %
Months From Randomization
0 5 10 15 20 25 30
0
10
20
40
60
80
100
30
50
70
90
HR = 0.59; 95% CI: 0.45-0.76
P < 0.0001
PFS: Double-blind Period1,2
(by Independent Central Review)
CI, confidence interval; HR, hazard ratio.
1. Brose MS, et al. Lancet. 2014;384(9940):319-328. 2. Brose MS, et al. Presented at ASCO 2013.